Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

May 23, 2024

https://www.globenewswire.com/news-release/2024/05/23/2887263/0/en/Inozyme-Pharma-to-Present-Recently-Announced-Data-from-Phase-1-2-Trials-of-INZ-701-in-Adults-with-ENPP1-Deficiency-and-ABCC6-Deficiency-PXE-at-Upcoming-Medical-Conferences.html

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq:INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company will present recently announced topline data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (manifesting as pseudoxanthoma elasticum, or PXE), during oral presentations at two upcoming medical conferences.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.